C.R. Bard
http://www.crbard.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From C.R. Bard
Biogen Leans On Pipeline As Tecfidera, Spinraza See Q4 Sales Dip
The company sees aducanumab adding a modest boost to sales if approved, but there are another four Phase III programs with some major read-outs coming.
Samsung Bioepis Opens New HQ To Drive Next-Generation Biosimilars
With a biosimilar Lucentis (ranibizumab) candidate recently filed and Soliris (eculizumab), Eylea (aflibercept) and Prolia (denosumab) candidates in Phase III development, Samsung Bioepis has moved into its new domestic headquarters to spearhead its journey to the next level.
Samsung Bioepis Calls For Improved Education On Biosimilars
Renewed efforts are needed to educate healthcare industry stakeholders about biosimilars, Samsung Bioepis has insisted, as the firm published a white paper detailing deficiencies in understanding on the part of patients and healthcare professionals.
Samsung Bioepis Moves Swiftly To Denosumab Phase III
Samsung Bioepis has announced that its SB16 biosimilar denosumab rival to Amgen’s Prolia has progressed to Phase III trials.
Company Information
- Industry
- Medical Devices
- Other Names / Subsidiaries
-
- Davol, Inc.
- Embo Medical Limited
- Liberator Medical, Inc.
- Lutonix, Inc.
- Medafor, Inc.
- Medicon, Inc.
- Neomend, Inc.
- Rochester Medical, Inc.
- Vascular Pathways, Inc.
- FlowCardia, Inc.
- Bridger Biomed, Inc.